个性化神经心理评估预测高级别胶质瘤疾病进展
结果显示认知下降者疾病进展风险是稳定者的5.05倍(p<0.01),提示简短的个体化认知评估可作为无创监测补充。
要点
- 个性化选择3项神经心理测试,至少2项RCI≤-1定义认知下降。
- 认知下降者疾病进展风险为稳定者的5.05倍(p<0.01)。
- 15例RANO确认进展者中9例(60%)在进展前或进展时出现认知下降。
核心结论
- 个性化选择的3项神经心理测试出现认知下降时,疾病进展风险较稳定表现增加5倍。
主要发现
- 15例RANO确认进展者中9例(60%)在进展前或进展时出现认知下降。
- 10例疾病稳定者中8例(80%)未出现认知下降。
- 认知下降预测进展的独立风险比为5.05(p<0.01)。
关键数值与推荐
- 个性化选择3项术后首次评估RCI值最高的测试。
- 后续随访中至少2项测试RCI≤-1定义为认知下降。
- 采用离散Cox比例风险模型,纳入时变认知下降系数和年龄协变量。
临床怎么用
- 简短个体化认知评估可作为高级别胶质瘤疾病监测的无创补充,不增加患者和临床负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Progressive disease in patients with high-grade glioma may be reflected in cognitive decline. However, the cognitive functions most sensitive to progression may differ between patients. We investigated whether decline on a personalized selection of tests predicted progressive disease according to RANO criteria in high-grade glioma patients. METHODS: Starting one day before surgery, patients underwent neuropsychological assessment every three months during standard treatment and clinical follow-up. We first made a personalized selection of three tests that showed the highest Reliable Change Index (RCI) values, i.e., most positive change, at the first post-surgical assessment for each patient. In subsequent follow up, a decline of RCI ≤ - 1 on at least two of the three tests in the selection was considered cognitive decline. We performed a discrete Cox proportional hazards model including a time-dependent coefficient cognitive decline (vs. stability) and covariate age to predict progressive disease. RESULTS: Twenty five patients were included. Cognitive decline on the personalized test selection preceded or had occurred by the time progression was established in 9/15 patients with RANO confirmed progressive disease (60%). Decline was absent in 8/10 patients (80%) with stable disease during participation. The independent hazard ratio for progression in case of cognitive decline was 5.05 (p < 0.01) compared to stable performance. CONCLUSIONS: Using only three patient-specific neuropsychological tests, we found a fivefold increased chance of disease progression in case of cognitive decline as compared to stable performance. Brief, patient-tailored cognitive assessment may be a noninvasive addition to disease monitoring without overburdening patients and clinical care.
引用
- Butterbrod E, Bruijn J, Braaksma MM, et al. Predicting disease progression in high-grade glioma with neuropsychological parameters: the value of personalized longitudinal assessment. J Neurooncol. 2019. PMID: 31342318. doi:10.1007/s11060-019-03249-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。